Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selectively kills tumor cells. However, its short half-life, poor delivery, and TRAIL-resistant tumor cells have diminished its clinical efficacy. In this study, we explored whether novel delivery methods will represent new and effectiv...

Full description

Saved in:

Bibliographic Details
Published in:	Molecular cancer therapeutics Vol. 7; no. 11; pp. 3575 - 3585
Main Authors:	Hingtgen, Shawn, Ren, Xianghui, Terwilliger, Ernie, Classon, Marie, Weissleder, Ralph, Shah, Khalid
Format:	Journal Article
Language:	English
Published:	United States American Association for Cancer Research 01-11-2008
Subjects:	AAV Antineoplastic Agents, Alkylating - administration & dosage Antineoplastic Agents, Alkylating - therapeutic use Cell Line, Tumor Dacarbazine - analogs & derivatives Dacarbazine - therapeutic use Dependovirus - genetics Genetic Therapy - methods Genetic Vectors - administration & dosage Glioma - drug therapy Glioma - metabolism Glioma - therapy Humans Microscopy, Fluorescence molecular imaging Signal Transduction stem cell Stem Cell Transplantation Stem Cells - cytology Stem Cells - metabolism Temozolomide TNF-Related Apoptosis-Inducing Ligand - genetics TNF-Related Apoptosis-Inducing Ligand - metabolism TRAIL Xenograft Model Antitumor Assays
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selectively kills tumor cells. However, its short half-life, poor delivery, and TRAIL-resistant tumor cells have diminished its clinical efficacy. In this study, we explored whether novel delivery methods will represent new and effective ways to treat gliomas and if adjuvant therapy with the chemotherapeutic agent temozolomide would enhance the cytotoxic properties of TRAIL in glioma lines resistant to TRAIL monotherapy. We have engineered adeno-associated virus (AAV) vectors encoding recombinant secreted TRAIL (S-TRAIL) and bioluminescent-fluorescent marker fusion proteins and show that AAV-delivered S-TRAIL leads to varying degrees of killing in multiple glioma lines, which correspond with caspase-3/7 activation. In vivo , dual bioluminescent imaging revealed efficient delivery of therapeutic AAV vectors directly into the tumor mass, which induced marked attenuation of tumor progression. Treatment of glioma cells with the chemotherapeutic agent temozolomide alone lead to a significant accumulation of cells in G 2 -M phase, activated the cell cycle checkpoint protein Chk1, and increased death receptor expression in a time-dependent manner. Furthermore, combined treatment with AAV-S-TRAIL or neural stem cell-S-TRAIL and temozolomide induced cell killing and markedly up-regulated proapoptotic proteins in glioma cells least sensitive to TRAIL. This study elucidates novel means of delivering S-TRAIL to gliomas and suggests combination of clinically relevant temozolomide and S-TRAIL may represent a new therapeutic option with increased potency for glioblastoma patients. [Mol Cancer Ther 2008;7(11):3575–85]
ISSN:	1535-7163 1538-8514
DOI:	10.1158/1535-7163.MCT-08-0640